We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Small molecule challenges dominance of TNF-α inhibitors.
- Authors
Sheridan, Cormac
- Abstract
The article discusses about R788, an oral rheumatoid arthritis drug being manufactured by Rigel Pharmaceutics passing its second phase testings. According to the article, R788 or tamatinib fodium, is an oral drug seen as a direct competitor of Tumor Necrosis Factor-alpha (TNF-α) inhibitors. The drug, considered safe and effective, has delivery advantages over TNF-α inhibitors as inhibitors often require injection procedures whereas R788 is to be taken orally. Following the positive results from the phase 2 trial of the South San Francisco-based manufactured drug, investors poured in and the stock in Nasdaq closed on December at $25.95 from previous day's result of $8.
- Subjects
SOUTH San Francisco (Calif.); CALIFORNIA; THERAPEUTICS research; MARKET value; ORAL medicine; RHEUMATOID arthritis; RHEUMATOID arthritis treatment; RIGEL Pharmaceuticals Inc.; TUMOR necrosis factors; THERAPEUTICS
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 2, p143
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0208-143